- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02701712
Receiving Radiation Therapy in the MRgRT Research Facility (MRgRT)
March 3, 2026 updated by: University Health Network, Toronto
The aim of this study is to evaluate the technical performance of magnetic-resonance guided radiotherapy (MRgRT) facility at the Princess Margaret Cancer Centre and the impact on the workflow of the clinical team in this facility.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
150
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Ability to provide informed consent
- Planned to receive clinical intervention (imaging or treatment) in the MRgRT facility
- At least 18 years of age
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Magnetic resonance - guided radiation therapy (MRgRT)
Magnetic resonance (MR) - guided radiation therapy
|
Use of magnetic resonance (MR) visualization for interventional radiotherapy in cancer patients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of planned patients receiving treatment in the MRgRT facility
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Measure tumor size before, during and after radiotherapy
Time Frame: 2 years
|
Collect and analyze imaging data before, during and after radiotherapy, and the related treatment data
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Michael Milosevic, MD, University Health Network, Toronto
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2016
Primary Completion (Estimated)
February 1, 2027
Study Completion (Estimated)
February 1, 2027
Study Registration Dates
First Submitted
February 22, 2016
First Submitted That Met QC Criteria
March 2, 2016
First Posted (Estimated)
March 8, 2016
Study Record Updates
Last Update Posted (Actual)
March 5, 2026
Last Update Submitted That Met QC Criteria
March 3, 2026
Last Verified
March 1, 2026
More Information
Terms related to this study
Other Study ID Numbers
- 14-8210-CE
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumors and Metastatic Lesions
-
Daiichi SankyoRecruitingSolid Tumors | Metastatic Solid TumorsJapan
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Japan, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Incyte CorporationActive, not recruitingAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States
-
Beijing BiotechRecruitingAdvanced Solid Tumors | Metastatic Solid Tumors | TROP2-Expressing Solid TumorsChina
-
NeuPharma, Inc.RecruitingLocally Advanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Chong Kun Dang PharmaceuticalRecruitingAdvanced Solid Tumors | Metastatic Solid TumorsSouth Korea
-
Trutino Biosciences Inc.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
Clinical Trials on Magnetic resonance - guided radiation therapy (MRgRT)
-
UMC UtrechtRecruitingEsophageal Squamous Cell Carcinoma (ESCC) | Esophageal Cancer, Squamous CellNetherlands
-
Abramson Cancer Center of the University of PennsylvaniaCompletedProstate Cancer | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the ProstateUnited States
-
Jonsson Comprehensive Cancer CenterActive, not recruitingProstate AdenocarcinomaUnited States
-
Washington University School of MedicineWithdrawn
-
Jonsson Comprehensive Cancer CenterRecruitingAbdominopelvic SarcomasUnited States
-
Wave NeuroscienceCompletedStress Disorders, Post-TraumaticUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); Viewray Inc.RecruitingStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Localized Prostate AdenocarcinomaUnited States
-
University of California, San FranciscoNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Institute of Cancer Research, United KingdomUnknown
-
Beijing Tiantan HospitalEnrolling by invitationDrug Resistant EpilepsyChina